Navigation Links
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
Date:12/7/2007

discontinuation of therapy

-- DOXIL is an irritant, not a vesicant; use precautions to avoid

extravasation

-- DOXIL can cause fetal harm when used during pregnancy

-- Recall reaction has occurred with DOXIL administration after

radiotherapy

-- DOXIL may interact with drugs known to interact with the conventional

formulation of doxorubicin HCl

-- In patients with multiple myeloma, the most common all-grade ARs

greater than or equal to 20%

(VELCADE plus DOXIL vs VELCADE, respectively) included: neutropenia

(36% vs 22%), thrombocytopenia (33% vs 28%), anemia (25% vs 21%),

fatigue (36% vs 28%), pyrexia (31% vs 22%), asthenia (22% vs 18%),

nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%),

constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral

neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash (22% vs 18%)

-- In addition, 19% vs <1% reported HFS Please see full Prescribing Information http://www.doxil.com/pdf/DOXIL_PI_Booklet.pdf, including Boxed WARNINGS.

DOXIL is marketed in the United States by Ortho Biotech Products, L.P., and in Israel by Janssen-Cilag. Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX(R) throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL, please visit http://www.DOXIL.com.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercial
'/>"/>

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... PRINCETON, N.J., Oct. 9 Impliant, Inc., a ... fusion surgery, announced today that it conducted the ... the newest addition to its product portfolio. ... ) , The system is comprised of the ...
... ... HHC Nutrition Services will pay the United States $1.375 million to ... assistance under the guise of a sham durable medical equipment (DME) ... Corp., and its affiliate MediNet Corp. provided the kickbacks and assistance ...
Cached Medicine Technology:Impliant Conducts the First Two Implantations of Its New TOPS VersaLink Spinal System 2Impliant Conducts the First Two Implantations of Its New TOPS VersaLink Spinal System 3Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
(Date:12/19/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Gliquidone manufacturers and is a valuable source of ... the industry. , Firstly, the report provides a basic ... manufacturing technology. Then, the report explores the international and ...
(Date:12/19/2014)... new study suggests a possible link between certain menopause ... sweats -- and higher rates of hip fractures and ... affecting about 60 percent of women. The hormonal changes ... then face a higher risk of weakened bones and ... or severe menopausal symptoms are more likely to have ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/17/2014)... 17, 2014 Dr. Myo Nwe is the ... Diet of the Future” and co-founder of the Ace Medical ... Dr. Nwe takes a broad look at the industry of ... under scientific scrutiny. On film and in television shows, however, ... toward the social aspects and played for basic laughs, which ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 A group ... Center for Longevity, today, in reaction to a recent statement ... science of brain training and derogated the efficacy of all ... they agreed with the parts of the center’s statement critical ... believed the center had also overstated its case, in a ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... investigates the challenges that pen and paper workarounds ... of electronic health records. Understanding these challenges may ... health IT. Focusing on referrals by primary ... specialists back to the referring physician, "Paper Persistence, ...
... The American Society of Clinical Oncology (ASCO) Annual Meeting, ... for treating recurrent gliobastoma (GBM) has a favorable safety ... more than the current median survival rate. Patients ... Center, University of California, San Francisco and Columbia University, ...
... the most vulnerable group are the elderly. Writing in ... in New Zealand suggest that emergency response plans must ... regards to the personal and social resources they have ... University in Palmerston North, point out that elderly citizens ...
... the arteries is one of the leading causes of death. ... growth of fibrous plaques, which leads to narrowing or occlusion ... The persistence of the inflammatory reaction is due to a ... So-called dendritic cells are known to play a central role ...
... quality care for young people do not always provide the ... found. As our population ages and requires more healthcare, ... for the over 65s and implement programs to meet their ... director at St. Michael,s Hospital. The study, published in ...
... HealthDay Reporter , THURSDAY, June 2 (HealthDay News) -- The ... bacteria in Europe should serve as a red flag ... mutating and changing. They,re not necessarily becoming more severe, but ... attending physician in infectious diseases at North Shore University Hospital ...
Cached Medicine News:Health News:Paper and computer workarounds challenge but may improve health IT 2Health News:Paper and computer workarounds challenge but may improve health IT 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 4Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 5Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 6Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 7Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 8Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 9Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 10Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 11Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 12Health News:Helping the aged during natural disasters 2Health News:Fast track to vascular disease 2Health News:Fast track to vascular disease 3Health News:Not all hospitals treat elderly the same 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Medicine Products: